Josh Bilenker ends his brief role in an unusual experiment at Eli Lilly, bowing out as head of their Loxo cancer R&D unit
A little more than a year since Josh Bilenker started an unusual experiment running Eli Lilly’s cancer research group following the $8 billion sale of his startup Loxo to the pharma giant, the biotech entrepreneur is wrapping up his part in the venture.
Lilly execs noted in their quarterly call today that Bilenker has opted to leave Loxo Oncology at Lilly in pursuit of other, unspecified, endeavors. In his place will be Jacob Van Naarden, Bilenker’s lieutenant among the group tapped to take up the reins of oncology.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,200+ biopharma pros reading Endpoints daily — and it's free.